|Bid price||11.00||Open price||11.00|
|Ask price||11.50||Prev close||11.00|
Register now for FREE live Plethora Solutions Holdings share prices, Plethora Solutions Holdings stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Plethora Solutions Holdings Level 2 Data, indepth research tools and investor commentary for Plethora Solutions Holdings (PLE) and other London Stock Exchange equities.
Register now for FREE Plethora Solutions Holdings share price charts
|Name||Plethora Solutions Holdings||Epic||PLE|
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B06GL868|
|Activites||Plethora Solutions Holdings plc is a publicly listed speciality pharmaceutical company with a portfolio of products for the treatment and management of urological disorders. Plethora's mission is to acquire, develop and market (either directly or with partners) products to bring clinical benefit to patients suffering from urological disorders. By fulfilling this mission the Company will build a profitable and sustainable business and yield value growth for shareholders. Plethora's corporate objectives will be realised through: * Licensing or selling rights to Plethora's clinical stage assets in return for milestone and royalty revenue streams ; * Building a profitable and growing, marketing and distribution subsidiary company The Urology Company whose product portfolio will be built by licensing and acquiring rights to products approved for the treatment and management of urological disorders in the UK market.||Index||n/a|
|Latest Share Price (p)||11.25||Net Gearing (%)||2,563.79|
|Market Capitalisation (£m)||45.68||Gross Gearing (%)||2,577.16|
|Shares in issue (m)||415.27||Debt Ratio||-11.81|
|P/E Ratio||-5.79||Debt-to-Equity Ratio||0.10|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||-0.04|
|Dividend Yield (%)||0.00||Price to book value||-7.94|
|Dividend cover (x)||0.00||ROCE||-12.85|
|Earning per share (p)||-1.90||EPS Growth (%)||0.00|
|52 week high / low||21.50 / 1.18||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|28/04/2011||PLAC||Dr Michael Wyllie||ED||333,333|
The FTSE 100 was down late today as a soft start to Wall St, along with ongoing market worries over the Ukraine situation and slowing growth in China, quickly erased mid-afternoon gains. Approaching the close, the FTSE 100 was down 2.04 points, or 0.03%, to 6687.41, while the FTSE 250 added...
FTSE indices were down with financial stocks losing as Bank of England governor Mark Carney defended the bank's forward-guidance policy, while supermarkets also suffered. Approaching midday, the FTSE 100 was down 18.15 points, or 0.27%, to 6671.3, while the FTSE 250 gave up 11.31 points, or...
Plethora said the US Food and Drug Administration has clearly defined the path to a successful submission of the New Drug Application for PSD 502, which is to treat premature ejaculation. "Importantly, the FDA has confirmed that premature ejaculation is an area of high medical need with a...
Register now for FREE Plethora Solutions Holdings company news
Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately. For those not familiar with this stock check on previous news over the last...
any one noticed this for a rise.
Register now for FREE Plethora Solutions Holdings share price discussions